Galectin Therapeutics Inc.
GALT
$1.37
$0.032.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.05% | 2.58% | -9.44% | 3.31% | -18.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.99% | -1.09% | 25.41% | -6.71% | -10.08% |
| Operating Income | -29.99% | 1.09% | -25.41% | 6.71% | 10.08% |
| Income Before Tax | -19.71% | -7.59% | -35.74% | 0.33% | 5.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.71% | -7.59% | -35.74% | 0.33% | 5.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.71% | -7.59% | -35.74% | 0.33% | 5.99% |
| EBIT | -29.99% | 1.09% | -25.41% | 6.71% | 10.08% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -17.90% | 23.30% | -29.74% | 4.28% | 9.67% |
| Normalized Basic EPS | -18.02% | -3.11% | -29.92% | 4.29% | 9.66% |
| EPS Diluted | -17.90% | 23.30% | -29.87% | 4.28% | 9.67% |
| Normalized Diluted EPS | -18.02% | -3.11% | -29.92% | 4.29% | 9.66% |
| Average Basic Shares Outstanding | 1.42% | 4.31% | 4.45% | 4.20% | 4.11% |
| Average Diluted Shares Outstanding | 1.42% | 4.31% | 4.45% | 4.20% | 4.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |